Home
Resource
Targeted nanomedicine platform for cancer stem cells specific therapy
PDF
PDF format is widely accepted and good for printing.
Plug-in required
PDF-1(2.89 MB)
Citation & Export
View Usage Statistics
Staff View

Citation & Export
Hide

Simple citation

Shah, Vatsal V.. Targeted nanomedicine platform for cancer stem cells specific therapy. Retrieved from https://doi.org/doi:10.7282/T35M64D5

Export

Click here for information about Citation Management Tools at Rutgers.

Statistics
Hide

Description

TitleTargeted nanomedicine platform for cancer stem cells specific therapy
NameShah, Vatsal V. (author); Minko, Tamara (chair); You, Guofeng (internal member); Hatefi, Arash (internal member); Dayan, Nava (outside member); Rutgers University; Graduate School - New Brunswick
Date Created2013
Other Date2013-01 (degree)
SubjectPharmaceutical Science, Genetic toxicology, Cancer--Treatment--Complications, Stem cells--Research, Nanomedicine, Drug delivery systems
Extentxx, 162 p. : ill.
DescriptionCancer is one of the most fatal diseases in the world. More than 10 million cases of cancer are reported every year. It is responsible for one in 4 deaths in the United States.The agents that are currently used for chemotherapy fail to differentiate between the cancerous and normal cells leading to numerous adverse side-effects. Owing to their toxicity, there is limitation to the amount of dose that can be administered. Due to the lack of specificity and restriction of dose, it sometimes becomes very difficult to achieve an effective concentration within the cancer affected tissues . One of the purposes of this proposal is to evaluate various drug delivery systems utilized in cancer therapy or diagnosis for genotoxicity. If a drug delivery system is found to be genotoxic, we propose to modify these genotoxic systems so as to reduce or completely eliminate their genotoxicity. We also propose to test certain raw materials used in cosmetic industry on a regular bases for genotoxicity. The other purpose of this study is to develop a dendrimer based drug delivery system that would specifically knock down CD44 in cancerous cells. Once CD44 is knocked down, we plan to treat the cancer cells specifically using a chemotherapeutic drug, Paclitaxel attached to PPi dendrimer.
NotePh.D.
NoteIncludes bibliographical references
Noteby Vatsal V. Shah
Genretheses, ETD doctoral
Persistent URLhttps://doi.org/doi:10.7282/T35M64D5
Languageeng
CollectionGraduate School - New Brunswick Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Version 8.5.5
Rutgers University Libraries - Copyright ©2024